Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
May your weight loss stay consistent, your side effects stay manageable, and your medication choice stay informed.
Benefits (Research Focus) Dual receptor agonism studied for simultaneous activation of GIP and GLP-1 receptors with imbalanced biased agonism Glycemic control research investigated for fasting glucose, HbA1c, and insulin sensitivity parameters in T2D models Body composition examined for fat-mass and lean-mass partitioning in obesity models Gastric emptying explored for delayed gastric transit and downstream satiety endpoints Long-acting profile C20 fatty diacid albumin-binding chemistry for extended half-life (~5 days) What Researchers Look At Receptor binding affinity and selectivity at GIPR vs GLP-1R cAMP and -arrestin recruitment in cell lines expressing each receptor subtype Food intake, body weight, and adipose-tissue change in DIO rodent models Gastric emptying time and gastrointestinal transit profiles Comparative pharmacology versus semaglutide, retatrutide, and other incretin analogs Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: Tirzepatide Synonyms: LY3298176
MK was an employee at Eli Lilly, during which she contributed to this article
A modern 503A compounding pharmacy
The GLP-1 injection process takes little effort, and the best part
